Biotronik’s new Selectra system approved in Europe

Biotronik's Selectra left ventricular lead delivery system has received regulatory approval for sale in Europe.

The device is a groundbreaking telescopic delivery system that utilises a slittable haemostatic valve to reduce the complexity involved in lead implantation, as well as minimising the likelihood of leads being moved as the sheath is taken out.

It features a unique handle design with an integrated side port, providing maximum flexibility and one-handed manipulation, as well as an enhanced shaft design and short soft tip to minimise dissection risks.

Other benefits of Selectra include its streamlined, fully integrated hub and friction-minimising hydrophilic inner coating.

Marlou Janssen, vice-president of global marketing and sales, said: "Biotronik spent considerable time understanding electrophysiologists' needs and examining the challenges they face with current lead delivery systems."

The medical technology firm is attending the European Society of Cardiology Congress this week, where it is presenting new trial data on clinical innovations such as its Biotronik Home Monitoring system.